2758 related articles for article (PubMed ID: 30246878)
1. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
2. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
3. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
[TBL] [Abstract][Full Text] [Related]
4. Interventions for people with type 2 diabetes mellitus fasting during Ramadan.
Lee SWH; Chen WS; Sellappans R; Md Sharif SB; Metzendorf MI; Lai NM
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013178. PubMed ID: 37435938
[TBL] [Abstract][Full Text] [Related]
5. Glucose targets for preventing diabetic kidney disease and its progression.
Ruospo M; Saglimbene VM; Palmer SC; De Cosmo S; Pacilli A; Lamacchia O; Cignarelli M; Fioretto P; Vecchio M; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010137. PubMed ID: 28594069
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Cooper TE; Teng C; Tunnicliffe DJ; Cashmore BA; Strippoli GF
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD007751. PubMed ID: 37466151
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
10. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
[TBL] [Abstract][Full Text] [Related]
11. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
12. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD001892. PubMed ID: 33118160
[TBL] [Abstract][Full Text] [Related]
13. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001892. PubMed ID: 30284724
[TBL] [Abstract][Full Text] [Related]
14. Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
Cooper TE; Khalid R; Chan S; Craig JC; Hawley CM; Howell M; Johnson DW; Jaure A; Teixeira-Pinto A; Wong G
Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013631. PubMed ID: 37870148
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological interventions for heart failure in people with chronic kidney disease.
Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
[TBL] [Abstract][Full Text] [Related]
16. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Tunnicliffe DJ; Palmer SC; Cashmore BA; Saglimbene VM; Krishnasamy R; Lambert K; Johnson DW; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007784. PubMed ID: 38018702
[TBL] [Abstract][Full Text] [Related]
17. Interventions for weight loss in people with chronic kidney disease who are overweight or obese.
Conley MM; McFarlane CM; Johnson DW; Kelly JT; Campbell KL; MacLaughlin HL
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013119. PubMed ID: 33782940
[TBL] [Abstract][Full Text] [Related]
18. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
19. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
20. Antioxidants for adults with chronic kidney disease.
Colombijn JM; Hooft L; Jun M; Webster AC; Bots ML; Verhaar MC; Vernooij RW
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD008176. PubMed ID: 37916745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
